1940P CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)?
| Autor: | Linossi, C., Funingana, I.G., Petruzzelli, M., Rala de Paula, B.H., O'Donovan, M., Andrea, M., Hewitt, S., Williams, A.L., Grehan, N., Redmond, A., Smyth, E.C., Baird, R.D., Godfrey, E.M., Di Pietro, M., Faull, I., Dovedi, S., Fitzgerald, R.C., Pacey, S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S1096-S1096 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|